Merck & Co. (MRK) Receives FDA Approval of LIPTRUZET as LDL Treatment in Certain Patients
Tweet Send to a Friend
Merck & Co., Inc. (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET (ezetimibe and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
